Scholarlink

Background <p>Triple-negative breast cancer (TNBC) lacks targeted therapies. FKBP10 contributes to oncogenesis and chemoresistance. We investigated FKBP10’s prognostic value in TNBC.</p> Methods <p>We retrospectively analyzed 190 TNBC patients receiving neoadjuvant chemotherapy. Patients were stratified by FKBP10 expression (median AOD cutoff) and TP53 status. Cox regression identified prognostic factors for disease-free survival (DFS) and pathological complete response (pCR).</p> Results <p>34% achieved pCR. High FKBP10 expression correlated with worse DFS (HR = 0.50, 95%CI: 0.26–0.96, <i>P</i> = 0.03). Independent predictors of DFS included: N-stage (<i>P</i> = 0.021), age (<i>P</i> = 0.027), FKBP10/TP53 co-occurrence (<i>P</i> = 0.020), and pCR status (<i>P</i> = 0.005). FKBP10/TP53 co-occurrence predicted poor chemotherapy response (OR = 0.413, <i>P</i> = 0.016).</p> Conclusion <p>FKBP10 overexpression with TP53 mutation predicts poor prognosis and chemoresistance in TNBC. These biomarkers may guide treatment decisions, though prospective validation is needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

FKBP10 expression and TP53 mutation predict prognosis and chemotherapy response in triple-negative breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月25日

查看全文
  • Yan Li,
  • Chi Zhang,
  • Jian Chen,
  • Gang Tu,
  • Lingfeng Tang

摘要

Background

Triple-negative breast cancer (TNBC) lacks targeted therapies. FKBP10 contributes to oncogenesis and chemoresistance. We investigated FKBP10’s prognostic value in TNBC.

Methods

We retrospectively analyzed 190 TNBC patients receiving neoadjuvant chemotherapy. Patients were stratified by FKBP10 expression (median AOD cutoff) and TP53 status. Cox regression identified prognostic factors for disease-free survival (DFS) and pathological complete response (pCR).

Results

34% achieved pCR. High FKBP10 expression correlated with worse DFS (HR = 0.50, 95%CI: 0.26–0.96, P = 0.03). Independent predictors of DFS included: N-stage (P = 0.021), age (P = 0.027), FKBP10/TP53 co-occurrence (P = 0.020), and pCR status (P = 0.005). FKBP10/TP53 co-occurrence predicted poor chemotherapy response (OR = 0.413, P = 0.016).

Conclusion

FKBP10 overexpression with TP53 mutation predicts poor prognosis and chemoresistance in TNBC. These biomarkers may guide treatment decisions, though prospective validation is needed.